Revised Cost Estimate (RCE) for OSDD project for the year 2014-2015 has been approved (RCE OM attached).
Shri Zakir Thomas, Project Director has repatriated to his parent department on 31st March, 2014 and the charge has been handed over to Dr Sarala Balachandran (Charge handover OM attached).
24 March 2014: Open Source Drug
Discovery launched the Phase II B clinical trials of the new
combination drug for TB -PaMZ in collaboration with the National Institute
of Tuberculosis & Respiratory Diseases, New Delhi. The proposed trial is a
three arm trial examining the safety and efficacy of the said combination on
multi-drug resistant tuberculosis in Indian patients. The protocols for the
Phase IIB clinical trials of PaMZ was released by Dr. T
Ramasami, Secretary , DST and Director General CSIR in presence of
Dr. V. M Katoch Secretary, Department of Health Research
& Director General, ICMR, Dr. Jagdish Prasad, Director
General of Health Services and Dr. Rohit Sarin , Director, NITRD. NITRD is the
Investigator institute and Dr Rohit Sarin is the Principal Investigator.
The Drug Controller General of India
has accorded approval for CSIR-OSDD’s proposal (OSDD-TBCT-001) to conduct a
Phase IIb clinical trial of a novel combination therapy for MDR TB patients.
The trial involves 3 arms, a new
combination of PA 824 in a combination of PA 824, Moxifloxacin and Pyrazinamide,
a second arm of Pa824 as an add on drug
to the current Standard of Care ( DOTS PLUS) and the 3rd arm
consisting of the Standard of Care. The new molecule and the novel combination
are brought into Clinical Trials in India in collaboration with Global Alliance
on Tuberculosis (TB Alliance). The trial is a partnership with National
Institute of Tuberculosis and Respiratory Diseases (formerly LRS Hospital),
Delhi, an institution under the Ministry of Health which is the Investigator
hospital. National Institute for Research in Tuberculosis (formerly TRC),
Chennai, an ICMR institute supported the design of the Trails. M/s G V K
Biosciences is the Clinical Research Organization supporting the Trials. If the
trials (including Phase III) are successful, the drugs will be available at an
affordable cost as it will be available for manufacture in India without any
royalty to OSDD.
The TATA CSIR-OSDD fellowship now offers a unique opportunity to students across the
universities to undertake research and contribute towards the OSDD vision of
providing affordable healthcare for all.
For more details and to apply for the fellowship please click here
On the invitation of the Norway Biotechnology Board, an
independent scientific body appointed by the Norwegian government, Prof. Samir
Brahmachari, Director General, CSIR and Chief Mentor, OSDD, delivered lecture on ‘Open Source Drug
Discovery as an Innovative Model for Affordable Healthcare for All’ at three
top universities of Norway. Prof. Brahmachari presented the concept of OSDD to
large audience at University of Oslo, University of Trondheim and University of
Tromso during 21-24th November 2013. In an interview with The Norwegian
Broadcasting Corporation, Prof. Brahmachari expressed his concern on the lack
of new drugs for neglected diseases like Tuberculosis and raising the hope of
innovative medical discoveries by involving young researchers in drug
to Prof. Brahmachari’s interview:
Bringing Together Global Volunteers for Affordable Drugs
Sir Dorabji Tata Trust
has awarded a Grant to enable Council of Scientific & Industrial Research
(CSIR), New Delhi for operating TATA CSIR-OSDD Fellowship (TCOF) to support
students and young researchers who will participate in the process of “crowd sourcing”
as a method of research on open source discovery of drugs for neglected
diseases like Tuberculosis (TB) and Malaria. The Grant amounts to Rs.285.75
lakhs for a period of 3 years.
An open source Operating System for drug discovery (customized Linux), developed by Dr. G.P.S Raghava's group (CSIR- IMTech ) is available for download. This integrates most of the open source/freely available computational tools for drug discovery and provides an, in silico platform for computer aided drug design. Click here to know more about OSDD Linux